Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies - Hu-Lowe, D D; Chen, E; Zhang, L; Watson, K D; Mancuso, P; Lappin, P (Cancer Res, 2011)
. 10.1158/1538-7445.AM2011-1362, 10.1158/0008-5472.CAN-10-1451